Immunome, Inc.
Market Cap
$2.02B
P/E Ratio
-9.44
EPS
$-2.43
Dividend Yield
0.00%
52-Week Range
$7.15 — $27.65
Volume
1.39M
Avg Volume
1.21M
Beta
2.14
Get alerted when IMNM hits your target price.
Free — enter your email to get started
P/E (TTM)
-9.44
Forward P/E
—
PEG Ratio
-0.55
P/S (TTM)
296.08
P/B (TTM)
3.22
P/FCF
-24.74
EV/EBITDA
-13.39x
EV/Sales
—
ROE (TTM)
-0.58%
ROA (TTM)
-0.31%
ROIC
-0.22%
Gross Margin
-6.30%
Operating Margin
-30.85%
Net Margin
0.00%
Debt/Equity
0.01
Current Ratio
14.69
EPS Growth (YoY)
+0.17%
Revenue Growth (YoY)
-1.00%
EPS Growth (3Y)
-0.37%
EPS Growth (5Y)
-0.26%
Sales Growth (3Y)
-0.12%
Sales Growth (5Y)
-0.07%
EPS Est (This Year)
$-2.50
EPS Est (Next Year)
$-2.19
Dividend Yield
—
Annual Dividend
—
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
—
Cash/Share
$7.48
Buy
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $35.29(53.8% upside)
Institutional %
103.95%
Inst. Net Change
24.45M
Insider Net Shares (90d)
—
Outstanding Shares
91.71M
Float
75.31M
Free Float %
82.12%
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
NASDAQ
IPO Date
2020-10-02
Employees
131
CEO
Clay Siegall
Index Membership
—
Website
https://immunome.com
Immunome, Inc. (IMNM) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $2.02B, a P/E ratio of -9.44, IMNM is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare IMNM against other stocks using dozens of fundamental and technical filters.
Immunome, Inc. (IMNM) has a trailing twelve-month (TTM) P/E ratio of -9.44. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Immunome, Inc. (IMNM) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Immunome, Inc. (IMNM) has a market capitalization of $2.02 billion, classifying it as a mid-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Buy" rating on Immunome, Inc. (IMNM) with an average score of 1.67 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $35.29 implies 53.8% upside from the current price.